神经科药物事先授权障碍与后果的范围综述
患者最常见后果为治疗延迟(60%)和疾病活动增加(25%),临床医生和行政人员最常见后果为时间负担。
要点
- 事先授权导致神经科患者治疗延迟(60%)和疾病活动增加(25%)。
- 临床医生(35%)和行政人员(15%)的主要负担是时间消耗。
- 使用临床药师或技术人员(20%)及健康系统专科药房(15%)是常见促进因素。
核心结论
- 事先授权可对神经疾病患者造成显著用药障碍,并给所有相关方带来负担。
主要发现
- 患者最常见后果为治疗延迟(60%)和疾病活动增加(25%)。
- 临床医生最常见后果为时间负担(35%),行政人员为时间负担(15%)。
- 最常见促进因素为使用临床药师或技术人员(20%)和健康系统专科药房(15%)。
临床怎么用
- 神经科智能体医生应关注事先授权导致的治疗延迟风险,并考虑临床药师或专科药房支持。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Prior authorization (PA) is widely used by insurers to control health care costs and promote high-value care, but it can create significant barriers to accessing medications. This is particularly concerning in neurology, where timely treatment is critical to avoid disease progression and optimize patient outcomes. OBJECTIVE: To assess the consequences, barriers, and facilitators of PA policies affecting access to pharmacologic treatment in 6 common neurologic conditions-Alzheimer disease, Parkinson disease, multiple sclerosis, migraine, cerebrovascular disease, and epilepsy-with focus on impacts on patients, clinicians, and administrators. EVIDENCE REVIEW: The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) reporting guidelines for scoping reviews were followed, and the study protocol was registered on Open Science Framework. MEDLINE and Embase were searched up to November 1, 2024, using Ovid for studies that assessed the role of PA as a primary or secondary outcome for the 6 included neurologic conditions, or for neurology broadly if strongly applicable to the study aim, after the signage of the Affordable Care Act in March 2010. Abstract screening and full-text review were done in duplicate. Key information was charted in extraction, including study characteristics, demographics, methods, results, and implications for relevant stakeholders. The results were aggregated and thematically analyzed. FINDINGS: A total of 364 studies were identified using our search strategy on Ovid, 278 records were screened, and 20 studies were included in this review. The most frequently identified consequences for patients were delays in care (60%) and increase in disease activity (25%). The most frequently identified consequence for clinicians (35%) and administrators (15%) was time burden. The most common facilitators were the use of clinical pharmacists or technicians (20%) and health system specialty pharmacies (15%). CONCLUSIONS AND RELEVANCE: According to the results of this scoping review, PA can contribute to significant access barriers for people with neurological conditions and is associated with burden for all stakeholders involved. Reforms to PA can work towards more equitable access to medications for patients.
引用
- Gotlieb E, Joseph B, Blank L, et al. Barriers and Consequences of Prior Authorization for Neurologic Medications: A Scoping Review. JAMA Neurol. 2026. PMID: 41359327. doi:10.1001/jamaneurol.2025.4560
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。